English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Myocardial Perfusion Scintigraphy (MPS) has dominated the field of noninvasive cardiac imaging for over three decades now and continues to do so largely due to the unparalleled evidence supporting its diagnostic and prognostic value in the management of coronary artery disease (CAD). In recent years, there has been a dramatic rise in the number of cardiac imaging procedures that are being undertaken. In the USA alone, over 10 million myocardial perfusion scans are being performed annually. This is driven by a need to be able to better risk stratify patients with suspected CAD, particularly those in the intermediate risk group in whom the clinical management decisions are often unclear. From a clinician’s standpoint, the value of MPS lies in its ability to clearly guide decisions regarding coronary revascularization; hence the clinical interest in this technique remains unabated over the years. Two of the most important factors affecting prognosis of patients with CAD are: the extent of myocardium at risk and left ventricular function. MPS by gated Single Photon Emission Computed Tomography (SPECT) is uniquely placed to provide important prognostic data on both these parameters. In patients with suspected CAD, MPS acts as an useful gatekeeper to invasive coronary angiography and has been shown to be cost-effective for this purpose. MPS also yields independent and incremental prognostic information to that obtained from clinical and stress ECG data. The prognostic value of the extent of myocardium at risk (as assessed by extent of reversible perfusion defects with Tl-201), and its subsequent relationship with cardiac death was initially described in a study of 100 patients with no known history of myocardial infarction who presented for evaluation of chest pain. Since then, there have been a multitude of studies documenting the ability of abnormal MPS in predicting future cardiac deaths, nonfatal myocardial infarction and revascularization. Equally, a negative/ normal MPS was shown to be associated with a good prognostic outcome. Of note, majority of the data regarding the diagnostic and prognostic utility of MPS comes from studies that included patients with significant CAD (either [50% or [70% luminal stenosis in major epicardial vessels).

Abnormal myocardial perfusion in the absence of anatomically significant coronary artery disease: Implications and clinical significance